L'édition de cet ISBN n'est malheureusement plus disponible.
Afficher les exemplaires de cette édition ISBNLes informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.
Frais de port :
Gratuit
Vers Etats-Unis
Description du livre Hardcover. Etat : new. N° de réf. du vendeur 9788847053120
Description du livre Etat : New. pp. 664. N° de réf. du vendeur 26126931030
Description du livre Etat : New. N° de réf. du vendeur ABLIING23Apr0316110326608
Description du livre Gebunden. Etat : New. N° de réf. du vendeur 5810983
Description du livre Etat : New. pp. 664 52:B&W 6.14 x 9.21in or 234 x 156mm (Royal 8vo) Case Laminate on White w/Gloss Lam. N° de réf. du vendeur 132607881
Description du livre Buch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This monograph gathers and evaluates data on adverse events (AEs) associated specifically with those 'biomedicines' - monoclonal antibodies, fusion proteins, and cytokines - that have recently entered therapeutic use in humans. All AEs observed when using each member of this new drug class are covered, with a view to improving understanding of pathogenesis, facilitating prevention, monitoring, and control, and contributing to the development of better drugs that provide benefits while minimizing risk. Further aspects here examined include the role of drug mechanisms of action and immunogenicity in relation to AEs outcome and induction of systemic syndromes. Additional data on AEs in off-label treatments are also considered.Electronic data sheets, downloadable from Springer Extra Materials platform, include more detailed safety data as well as additional basic information on product characteristics, pre- and post-marketing AEs classified according to frequency, and system/organ targeting. Data on excipients and selected information on drug interactions and associations are also provided. Adverse Events with Biomedicines: Prevention Through Understanding will serve as a detailed, practical guideline to this important new area, which demands the attention of clinicians, immunologists, oncologists, allergologists, public health professionals, and drug companies. 664 pp. Englisch. N° de réf. du vendeur 9788847053120
Description du livre Etat : New. PRINT ON DEMAND Book; New; Fast Shipping from the UK. No. book. N° de réf. du vendeur ria9788847053120_lsuk
Description du livre Buch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - This monograph gathers and evaluates data on adverse events (AEs) associated specifically with those 'biomedicines' - monoclonal antibodies, fusion proteins, and cytokines - that have recently entered therapeutic use in humans. All AEs observed when using each member of this new drug class are covered, with a view to improving understanding of pathogenesis, facilitating prevention, monitoring, and control, and contributing to the development of better drugs that provide benefits while minimizing risk. Further aspects here examined include the role of drug mechanisms of action and immunogenicity in relation to AEs outcome and induction of systemic syndromes. Additional data on AEs in off-label treatments are also considered.Electronic data sheets, downloadable from Springer Extra Materials platform, include more detailed safety data as well as additional basic information on product characteristics, pre- and post-marketing AEs classified according to frequency, and system/organ targeting. Data on excipients and selected information on drug interactions and associations are also provided. Adverse Events with Biomedicines: Prevention Through Understanding will serve as a detailed, practical guideline to this important new area, which demands the attention of clinicians, immunologists, oncologists, allergologists, public health professionals, and drug companies. N° de réf. du vendeur 9788847053120